European Organisation for Research and Treatment of Cancer
Budget
€49,600,000
EP Access
0
accredited persons
Staff
3
0.45 FTE
EU Grants
None
Mission & Goals
The European Organisation for Research and Treatment of Cancer (EORTC) has delivered investigator driven, changing practice clinical trials since 1962. Its mission is to improve survival and quality of life of cancer patients. The EORTC is a not-for-profit independent organisation performing multidisciplinary clinical research activities across tumor types. The EORTC aims to improve the standard of cancer treatment through the testing of more effective therapeutic strategies based on drugs, surgery and/or radiotherapy that are already in use. EORTC’s activities involve on a voluntary basis more than 3000 medical doctors and scientists from some 900 university hospitals in 35 countries. EORTC clinical trials are involving several thousands of cancer patients on a yearly basis. The EORTC operates on an independent basis, and in this capacity is able to work in partnership with the pharmaceutical industry in evaluating innovative molecules.
EU Legislative Interests
- Artificial Intelligence Act - Biotech Act - Clinical Trials Regulation. - Early access to medicines: PRIME, accelerated assessment, conditional market authorization. - EU Beating Cancer plan. - EU Cancer Mission. - EU Partnership for Health Innovation. - EU pharmaceutical legislation - EU Roadmap for a pharmaceutical strategy for Europe. - Euratom and radioprotection. - European Health Data Space - General Data Protection Regulation. - Good Clinical Practice implementation. - Medical Device Regulation - Pharmaceutical strategy for Europe - Regulation of the European Parliament and of the Council on in vitro diagnostic medical devices. - Regulation on Health Technology Assessment.
Communication Activities
Participation in workshops and conference involving EU institutions officials. Position statement in collaboration with stakeholders groups such European Cancer Organisation, European Alliance for Personalised Medicine, BioMedAlliance, Rare Cancers Europe, EFGCP, European Data in Health Research Alliance, European Federation of Pharmaceutical Industries, FIPRA. EORTC is represented in the following working groups: Commission Expert Group on Clinical Trials, Commission HTA stakeholders pool, EMA CTIS new delivery model, EMA EV- Expert Working Group, Accelerating clinical trials in the EU (ACT EU) initiative, Clinical Trials Coordination Group expert group ‘Patient Involvement’. The EORTC is co-chairing the Cancer Medicines Forum together with the European Medicines Agency (EMA) which aims to advance treatment optimisation for approved cancer medicines. This includes by identifying and prioritizing research questions as well as policy issues emerging from the academic community
Interests Represented
Does not represent commercial interests
Member Of
American Association for Cancer Research American Society for Therapeutic Radiology and Oncology European Alliance for Personnalised Medicine European Association for NeuroOncology European Association of Urology European Association of Urology European Cancer Organisation European Forum for Good Clinical Practice European Oncology Nursing Society European School of Oncology European Society for Medical Oncology European Society for Therapeutic Radiology and Oncology European Society of Pathology European Society of Radiology International Network for Cancer Research and Treatment International Society of Geriatric Oncology International Society of Pediatric Oncology International Union Against Cancer Organisation of European Cancer Institutes
Organisation Members
Our members are medical doctors and/or scientists affiliated to some 800 university hospitals that are participating to EORTC clinical and translational research activities. https://www.eortc.org/members/
Commissioner Meetings
No recorded meetings with EU commissioners.